Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Pherecydes Pharma logo — At the forefront of the fight against antibioresistant bacte...

Pherecydes Pharma

At the forefront of the fight against antibioresistant bacteria

Founded 2006 France France 8 employees Grant Total: $16.00M Biotechnology, Health Care +1

General Information

Company Name Pherecydes Pharma
Founded Year 2006
Location France France +2
Founders / Decision Makers
Team member Team member
Employees 8
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Grant
Social

Get notified when Pherecydes Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Pherecydes Pharma

Pherecydes Pharma is a biotechnology startup based in France, founded in 2006, that is making strides in combating antibiotic-resistant bacteria. The company's innovative approach revolves around developing antibacterial treatments using bacteriophages (phages) to combat bacterial infections in humans, particularly those resistant to antibiotics. This is crucial as antimicrobial resistant bacteria (AMR) are responsible for over 700,000 deaths annually as of 2014, a number that could escalate to over 10,000,000 by 2050 if left unchecked. Notably, no new class of antibiotics has been discovered in the last 30 years, making Pherecydes Pharma's work all the more pivotal. The company's emphasis on precision phagotherapy, tailoring treatments to suit each patient by considering the activity of the phages on the specific bacterial strain responsible for the infection, is highly promising. Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli are the priority bacterial targets identified by the World Health Organization due to their danger and prevalence in industrialized countries, making them prime candidates for Pherecydes Pharma's interventions. Remarkably, some of the patented phages developed by Pherecydes Pharma have already been administered under the supervision of French Health authorities (ANSM) as part of compassionate treatments. Recent investment news also highlights the company's potential, with Bpifrance providing a €2.00M grant investment in January 2022. This injection of capital signifies the recognition of Pherecydes Pharma's promise in the biotechnology and healthcare sectors, positioning it as a noteworthy player in the ongoing battle against antibiotic-resistant bacteria.

Taxonomy: Pherecydes Pharma, bacteriophage viruses, AMR infections, precision phagotherapy, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, nosocomial infections, antibioresistant bacteria treatments, individualized treatments, WHO, compassionate treatments, French Health authorities, antibiotic resistance, bacterial infections

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
03 Jan 2022
Series B •••••• 6
Investor Investor Investor Investor Investor Investor
16 Jan 2018
Venture Round •••••• 2
Investor Investor
18 Mar 2015
Series A •••••• 1
Investor
01 Dec 2014
Grant •••••• - 18 Jan 2012

Pherecydes Pharma Alternatives & Competitors

Pherecydes Pharma vs
Biocidium Biopharmaceuticals
Biocidium Biopharmaceuticals Canada

Clinical-stage biopharmaceutical company focused on novel antibiotics, antifungals, and treatments f...

1 employees
Biopharma, Biotechnology
Pherecydes Pharma vs
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics United States

To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cures for ba...

Acquired
28 employees
Biotechnology, Health Care
Pherecydes Pharma vs
Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals United States

Fighting against antimicrobial resistance is at the core of our technology and our people.

Grant
14 employees
Biopharma, Biotechnology

FAQ About Pherecydes Pharma

At the forefront of the fight against antibioresistant bacteria
Pherecydes Pharma was founded in 2006.
Pherecydes Pharma is headquartered in France.
Pherecydes Pharma operates in the following industries: Biotechnology, Health Care, Medical Devices.
Pherecydes Pharma has approximately 8 employees.
Pherecydes Pharma has completed 5 funding rounds, raising a total of $16.00M. The latest funding stage is Grant.
Top alternatives and competitors to Pherecydes Pharma include Biocidium Biopharmaceuticals, Adaptive Phage Therapeutics, Tetraphase Pharmaceuticals, Inhalon Biopharma, Skin Laundry. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pherecydes Pharma and Biocidium Biopharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Pherecydes Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes